TY - JOUR
T1 - Magnetic resonance-guided stereotactic body radiation therapy for pancreatic oligometastases from renal cell carcinoma
AU - van Vulpen, Jonna K.
AU - Eijkelenkamp, Hidde
AU - Grimbergen, Guus
AU - Wessels, Frank J.
AU - Mulder, Sasja F.
AU - Meijer, Gert J.
AU - Intven, Martijn P.W.
N1 - Publisher Copyright:
© 2024
PY - 2024/10
Y1 - 2024/10
N2 - Stereotactic body radiation therapy (SBRT) may be a non-invasive strategy to treat patients with pancreatic oligometastases from renal cell carcinoma (RCC). We analyzed 11 patients treated with MR-guided SBRT to 31 pancreatic oligometastases. At a median follow-up of 31.6 months, 1-year and 2-year freedom from local progression was 100 % and 95 % (95 % CI 86–100 %), respectively. Moreover, 1-year and 2-year freedom from systemic therapy was 91 % (95 %CI 75–100 %) and 82 % (95 % CI 62–100 %), respectively. MR-guided SBRT may be a safe and effective treatment option for pancreatic oligometastases from RCC.
AB - Stereotactic body radiation therapy (SBRT) may be a non-invasive strategy to treat patients with pancreatic oligometastases from renal cell carcinoma (RCC). We analyzed 11 patients treated with MR-guided SBRT to 31 pancreatic oligometastases. At a median follow-up of 31.6 months, 1-year and 2-year freedom from local progression was 100 % and 95 % (95 % CI 86–100 %), respectively. Moreover, 1-year and 2-year freedom from systemic therapy was 91 % (95 %CI 75–100 %) and 82 % (95 % CI 62–100 %), respectively. MR-guided SBRT may be a safe and effective treatment option for pancreatic oligometastases from RCC.
KW - MR-guided SBRT
KW - Oligometastases
KW - Pancreatic metastases
KW - Renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85210543267&partnerID=8YFLogxK
U2 - 10.1016/j.phro.2024.100683
DO - 10.1016/j.phro.2024.100683
M3 - Article
AN - SCOPUS:85210543267
SN - 2405-6316
VL - 32
JO - Physics and Imaging in Radiation Oncology
JF - Physics and Imaging in Radiation Oncology
M1 - 100683
ER -